Thursday, September 1, 2022

In contrast to conventional studies of amyloidogenic drugs, quercetin accelerates fibrillation of prion protein. (A GOOD thing.)

QUERCETIN

Some highlights regarding Quercetin and amyloids:

Quercetin binding to prion protein is determined, and the network of the binding site at the molecular level is visualized.

In contrast to conventional studies of amyloidogenic drugs, quercetin accelerates fibrillation of prion protein. (A GOOD thing.)

Quercetin turns fibrils into protease-sensitive, structurally loose and non-cytotoxic forms.

Quercetin shows its uniqueness from typical antiamyloidogenic drugs.

Quercetin treatment can disaggregate moPrP (mouse prion) fibrils and lead to the formation of the proteinase-sensitive amorphous aggregates. Furthermore, quercetin-bound fibrils can reduce the membrane disruption of erythrocytes.

Quercetin is distinct from the typical function of antiamyloidogenic drugs that inhibit the formation of amyloid fibrils.

CURCUMIN

Curcumin may be a powerful alloy and “wing man” to Quercetin.

Curcumin alone reduced prion fibril formation significantly.

Curcumin effectively rescues the cells from apoptosis and decreases the ROS level caused by subsequent co-incubation with prion amyloid fibrils.

I believe urgent clinical trials are needed to assess the efficacy of Quercetin and Curcumin as prophylaxis, and treatment of both Acute and Long COVID.

https://www.sciencedirect.com/science/article/pii/S0753332222005662#

https://pubmed.ncbi.nlm.nih.gov/33187342/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235698/

Vaccine injured Orthopedic Surgeon Dr. Joel Wallskog shares the stories the media won’t let you hear

Drs. Cowan, Kaufman, Mr. Young and Ms. Massey have been given the opportunity to discuss Terrain vs. Germ Theory with McCairn. No shows.

BofA Is So Very Davos

CONFLICT OF INTEREST: In the US, the FDA [the drug regulator] takes 65% of its money from the drug industry. In Britain, the MHRA takes 86%.

The host is Maajid Nawaz.  The guest is Cardiologist, Dr. Aseem Malhotra.

Very, very bad in the corruption.  They will design the trials that are likely to given them the outcome that they want.  They then hold onto the raw data, and often what's interesting is what people don't know is that the very data that drives the conclusion of the trial that then are approved by the regulator, we'll come to the regulatory in a minute. they keep that confidential.  And historically, when independent researchers have been able to access that raw data through litigation or through campaigns and looked at that data that drove the results of the trial that suggested the drug was positive, it would reverse the conclusion.  So, something that was thought to be safe today, tomorrow is then found to be the opposite: not safe, and not very effective.  So that's just giving you a snapshot of how important getting the raw data is.  So, they control the data.  We have to trust their summary results.  The regulator, the BMJ did an investigation on this a couple of weeks ago to expose . . . by Maryanne Demasi, who is prolific in medical investigations, "From FDA to MHRA: Are Drug Regulators for Hire?" she's done that for many years.  

Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit the market.  But do they have sufficient independence from the companies they are meant to regulate?  

And what they found was that most of the major regulators of the western countries are funded by the drug industry.  So, the FDA takes about 65% of their money from the drug industry.  The MHRA [a British regulatory agency] in this country, 86%.  So, this is a big conflict of interest.  

Over the past decades, regulatory industries have seen large proportions of their budgets funded by the industries they are sworn to regulate. 

That's the medicines and health medicines of the MRHA . . .

In Europe, industry fees funded 20% of the new EU-wide regulator, the European Medicines Agency, (EMA), in 1995.  By 2010, that had risen to 75%; today, it's 89%. 

We need to dissociate; they need to be publicly funded bodies.  The drug industry can produce drugs, but they then shouldn't be able to test them, then hide the data, and then we just rely on the information that they give us for their profit-making incentives.

A prime example of what he's talking about.